IMS 2026 Annual Meeting
Trials whose public commentary places their results at IMS 2026 Annual Meeting, Sep 23–26, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
13 trials: 3 with reports and 10 with no report yet. Organised by International Myeloma Society (IMS); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Multiple myeloma · 3 | |||||||
| EXCALIBER-RRMM iberdomide plus daratumumab placed at IMS 2026 Annual Meeting by 12 sources NCT04975997 · Celgene | relapsed or refractory multiple myeloma | Phase 3 | 579 | 105 | Deep | Nov 1, 2026 | Preview |
| MELT-MM mezigdomide plus elranatamab plus dexamethasone placed at IMS 2026 Annual Meeting by 5 sources NCT06645678 · YOUNGIL KOH | relapsed/refractory multiple myeloma | Phase 1/Phase 2 | 54 | 14 | Focused | Nov 1, 2026 | Preview |
| IFM 2022-01 teclistamab plus lenalidomide; talquetamab plus teclistamab placed at IMS 2026 Annual Meeting by 2 sources NCT06353022 · Nantes University Hospital | newly diagnosed multiple myeloma | Phase 2 | 17 | 4 | Focused | Nov 1, 2026 | Preview |
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Multiple myeloma · 9 | |||||||
| CERVINO etentamig (ABBV-383) placed at IMS 2026 Annual Meeting by 16 sources NCT06158841 · AbbVie DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| CARTITUDE-2 ciltacabtagene autoleucel placed at IMS 2026 Annual Meeting by 9 sources NCT04133636 · Janssen Research & Development, LLC DeepView → | multiple myeloma | Phase 2 | Deep | View | |||
| MajesTEC-3 teclistamab plus daratumumab placed at IMS 2026 Annual Meeting by 9 sources NCT05083169 · Janssen Research & Development, LLC DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| IBEX iberdomide plus daratumumab (subcutaneous) placed at IMS 2026 Annual Meeting by 6 sources NCT06107738 · Barbara Ann Karmanos Cancer Institute StandardView → | multiple myeloma after autologous stem cell transplant | Phase 2 | Standard | View | |||
| MajesTEC-5 teclistamab plus daratumumab plus lenalidomide plus dexamethasone; talquetamab plus daratumumab plus lenalidomide plus dexamethasone; ramantamig (JNJ-79635322) plus daratumumab plus lenalidomide plus dexamethasone placed at IMS 2026 Annual Meeting by 6 sources NCT05695508 · University of Heidelberg Medical Center DeepView → | transplant-eligible newly diagnosed multiple myeloma | Phase 2 | Deep | View | |||
| MIDAS isatuximab plus carfilzomib plus lenalidomide plus dexamethasone placed at IMS 2026 Annual Meeting by 3 sources NCT04934475 · Intergroupe Francophone du Myelome DeepView → | newly diagnosed multiple myeloma eligible for autologous transplantation | Phase 3 | Deep | View | |||
| DREAMM-9 belantamab mafodotin plus bortezomib plus lenalidomide plus dexamethasone placed at IMS 2026 Annual Meeting by 2 sources NCT04091126 · GlaxoSmithKline DeepView → | newly diagnosed multiple myeloma | Phase 1 | Deep | View | |||
| IRAKLIA subcutaneous isatuximab placed at IMS 2026 Annual Meeting by 2 sources NCT05405166 · Sanofi DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| LINKER-MM1 linvoseltamab placed at IMS 2026 Annual Meeting by 2 sources NCT03761108 · Regeneron Pharmaceuticals DeepView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| Prostate cancer · 1 | |||||||
| EXCALIBUR Drug not named yet placed at IMS 2026 Annual Meeting by 3 sources NCT04915508 · Jonsson Comprehensive Cancer Center DeepView → | prostate cancer with rising PSA after radical prostatectomy | Phase 2 | Deep | View | |||